Literature DB >> 1460734

Antidepressant medications and the relative risk of suicide attempt and suicide.

S Kapur1, T Mieczkowski, J J Mann.   

Abstract

OBJECTIVE: Suicide by drug overdose is a major public health problem, and antidepressant medications are the most common agent involved. European studies suggest differences in the rates of suicide by overdose among antidepressants, but no reports have been published for the United States. We estimated the comparative risks of suicide attempts and suicides, and the relative risk of fatality in the event of an overdose for the major antidepressants currently marketed in the United States. DATA SOURCES: Information regarding suicide attempts and suicides by antidepressant overdose was obtained from the published reports of the Drug Abuse and Warning Network and the annual report of the American Association of Poison Control Centers, and corrected for differences in total annual prescriptions using data from the National Prescription Audit.
RESULTS: The risk of a suicide attempt did not appear to differ among antidepressants. The tricyclic antidepressants were associated with a higher rate of death in the event of an overdose than the newer nontricyclic antidepressants in both the annual report of the American Association of Poison Control Centers and the Drug Abuse and Warning Network data. The chance of death after an overdose was greater for desipramine hydrochloride than for other tricyclics.
CONCLUSION: The higher risk of suicide with tricyclics vs nontricyclics may be explained by a higher rate of death from overdose rather than more suicide attempts. Tricyclics carry the risk of greater cardiotoxicity. The basis for the even higher rate of death/overdose of desipramine is not known and requires further research. If these findings are replicated in a case-control study design, they have important implications for the choice of an antidepressant for the depressed patient at risk for suicidal behavior.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1460734

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  36 in total

Review 1.  Pharmacological treatment of depression in children and adolescents.

Authors:  R L Findling; M D Reed; J L Blumer
Journal:  Paediatr Drugs       Date:  1999 Jul-Sep       Impact factor: 3.022

Review 2.  Suicidality with selective serotonin reuptake inhibitors: Valid claim?

Authors:  Yvon D Lapierre
Journal:  J Psychiatry Neurosci       Date:  2003-09       Impact factor: 6.186

3.  Association of suicide and antidepressant prescription rates in Japan, 1999-2003.

Authors:  Atsuo Nakagawa; Michael F Grunebaum; Steven P Ellis; Maria A Oquendo; Haruo Kashima; Robert D Gibbons; J John Mann
Journal:  J Clin Psychiatry       Date:  2007-06       Impact factor: 4.384

4.  Suicidal antidepressant overdoses: a comparative analysis by antidepressant type.

Authors:  Nicole White; Toby Litovitz; Cathleen Clancy
Journal:  J Med Toxicol       Date:  2008-12

Review 5.  Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement.

Authors:  Hans-Jürgen Möller; David S Baldwin; Guy Goodwin; Siegfried Kasper; Ahmed Okasha; Dan J Stein; Rajiv Tandon; Marcio Versiani
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-08       Impact factor: 5.270

6.  Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data?

Authors:  N A Buckley; P R McManus
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

7.  Molecular epidemiology of major depressive disorder.

Authors:  Chikako Kiyohara; Kouichi Yoshimasu
Journal:  Environ Health Prev Med       Date:  2009-01-20       Impact factor: 3.674

Review 8.  A risk-benefit assessment of pharmacotherapies for clinical depression in children and adolescents.

Authors:  J Renaud; D Axelson; B Birmaher
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

Review 9.  Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression.

Authors:  P Mourilhe; P E Stokes
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

Review 10.  Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy.

Authors:  S M Holliday; G L Plosker
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.